C P Belani

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lu
    Chandra P Belani
    University of Pittsburgh Medical Center Cancer Pavilion, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    J Clin Oncol 23:3760-7. 2005
  2. ncbi Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel
    Chandra P Belani
    University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Lung Cancer 50:S3-8. 2005
  3. ncbi Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326)
    Chandra P Belani
    Lung and Thoracic Malignancies Program, University of Pittsburgh Cancer Institute, PA 15232, USA
    Cancer 104:2766-74. 2005
  4. ncbi Challenges in advanced NSCLC: optimizing platinum-based chemotherapy and treating special populations
    Chandra P Belani
    Lung and Thoracic Cancer Program, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    J Natl Compr Canc Netw 2:S10-22. 2004
  5. ncbi Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol
    Chandra P Belani
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    J Clin Oncol 23:5883-91. 2005
  6. ncbi Integration of docetaxel in the management of non-small-cell lung cancer
    Chandra P Belani
    University of Pittsburgh School of Medicine, and Lung and Thoracic Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Lung Cancer 46:S1-2. 2004
  7. ncbi Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer
    C P Belani
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, and The Jewish Hospital Kenwood, Cincinnati, OH, USA
    Ann Oncol 18:110-5. 2007
  8. ncbi Development of docetaxel in advanced non-small-cell lung cancer
    Chandra P Belani
    University of Pittsburgh School of Medicine, and Lung and Thoracic Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Lung Cancer 46:S3-11. 2004
  9. ncbi Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer
    C P Belani
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Ann Oncol 16:1069-75. 2005
  10. ncbi Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group
    Chandra P Belani
    University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Clin Lung Cancer 6:43-7. 2004

Collaborators

Detail Information

Publications82

  1. ncbi Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lu
    Chandra P Belani
    University of Pittsburgh Medical Center Cancer Pavilion, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    J Clin Oncol 23:3760-7. 2005
    ..To compare once-daily radiation therapy (qdRT) with hyperfractionated accelerated radiation therapy (HART) after two cycles of induction chemotherapy...
  2. ncbi Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel
    Chandra P Belani
    University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Lung Cancer 50:S3-8. 2005
    ..Based on the efficacy of platin-docetaxel regimens in advanced disease, they are now being incorporated into the adjuvant and neoadjuvant treatment of early-stage disease...
  3. ncbi Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326)
    Chandra P Belani
    Lung and Thoracic Malignancies Program, University of Pittsburgh Cancer Institute, PA 15232, USA
    Cancer 104:2766-74. 2005
    ..DC and docetaxel-carboplatin (DCb) were better tolerated than VC. We analyzed the efficacy and toxicity in patients ages < 65 and > or = 65 years...
  4. ncbi Challenges in advanced NSCLC: optimizing platinum-based chemotherapy and treating special populations
    Chandra P Belani
    Lung and Thoracic Cancer Program, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    J Natl Compr Canc Netw 2:S10-22. 2004
    ..A phase III trial comparing these schedules has been completed and will be reported in 2004...
  5. ncbi Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol
    Chandra P Belani
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    J Clin Oncol 23:5883-91. 2005
    ..Survival data were compared with historical standard sequential chemoradiotherapy data from the Radiation Therapy Oncology Group...
  6. ncbi Integration of docetaxel in the management of non-small-cell lung cancer
    Chandra P Belani
    University of Pittsburgh School of Medicine, and Lung and Thoracic Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Lung Cancer 46:S1-2. 2004
  7. ncbi Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer
    C P Belani
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, and The Jewish Hospital Kenwood, Cincinnati, OH, USA
    Ann Oncol 18:110-5. 2007
    ....
  8. ncbi Development of docetaxel in advanced non-small-cell lung cancer
    Chandra P Belani
    University of Pittsburgh School of Medicine, and Lung and Thoracic Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Lung Cancer 46:S3-11. 2004
    ..Non-platinum doublets such as docetaxel-gemcitabine have also demonstrated efficacy and safety. Docetaxel has undergone extensive evaluation and is the only agent approved for use in both first- and second-line therapy of advanced NSCLC...
  9. ncbi Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer
    C P Belani
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Ann Oncol 16:1069-75. 2005
    ....
  10. ncbi Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group
    Chandra P Belani
    University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Clin Lung Cancer 6:43-7. 2004
    ..There were 3 early deaths associated with the treatment regimen: severe gastrointestinal toxicity, hemorrhage, and an acute pulmonary event. Docetaxel as a single agent does not demonstrate evidence of activity in malignant mesothelioma...
  11. ncbi Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams
    S Bahri
    Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pennsylvania, USA
    Radiat Oncol Investig 7:297-308. 1999
    ..Our five-field conformal 3-DRTP technique, which incorporates treatment planning by dose/volume histogram (DVH) was associated with minimal toxicity and may facilitate dose escalation to the gross tumor...
  12. ncbi Paclitaxel for non-small cell lung cancer
    Sakkaraiappan Ramalingam
    University of Pittsburgh School of Medicine, PA, USA
    Expert Opin Pharmacother 5:1771-80. 2004
    ..Paclitaxel has also demonstrated synergistic interaction with several molecularly-targeted agents and is at present being evaluated in the neoadjuvant and adjuvant treatment settings for early stage NSCLC...
  13. ncbi Taxanes for advanced non-small cell lung cancer
    Sakkaraiappan Ramalingam
    Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Expert Opin Pharmacother 3:1693-709. 2002
    ..Several ongoing trials are comparing the efficacy of combining molecularly targeted agents with taxane-based regimens for the treatment of advanced NSCLC...
  14. ncbi Paclitaxel and docetaxel combinations in non-small cell lung cancer
    C P Belani
    Division of Medical Oncology, Department of Medicine, University of Pittsburgh School of Medicine, and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Chest 117:144S-151S. 2000
    ..Future research will look to refine the use of taxane combinations in NSCLC and to examine the potential of these unique and promising drugs when combined with newer agents that are active against this disease...
  15. ncbi Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trial
    Suresh Ramalingam
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    J Thorac Oncol 1:240-4. 2006
    ..5% and 1.1% in the <70 years cohort in arm 1. CONCLUSION: The weekly regimen of paclitaxel administered in combination with carboplatin is tolerated well by elderly NSCLC patients and has comparable efficacy with younger patients...
  16. ncbi Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer
    M K Mohamed
    Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Ann Oncol 16:780-5. 2005
    ..0002). The other factors did not impact survival. CONCLUSIONS: Occurrence of skin rash and baseline PS of 0/1 were associated with improved survival with gefitinib for recurrent NSCLC patients at our institution...
  17. ncbi Combined modality therapy for unresectable stage III non-small cell lung cancer: new chemotherapy combinations
    C P Belani
    Division of Medical Oncology, Department of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Chest 117:127S-132S. 2000
    ..This will likely be achieved through the optimization of chemotherapy regimens to be used in combined modality therapy with thoracic radiation therapy...
  18. ncbi A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies
    Suresh S Ramalingam
    Authors Affiliations Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Clin Cancer Res 14:3456-61. 2008
    ..We conducted a phase I study in patients with advanced malignancies to determine the recommended phase II dose of the combination of 17-AAG and paclitaxel...
  19. ncbi Multivariate analysis of survival, local control, and time to distant metastases in patients with unresectable non-small-cell lung carcinoma treated with 3-dimensional conformal radiation therapy with or without concurrent chemotherapy
    Michal J Wolski
    Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Clin Lung Cancer 7:100-6. 2005
    ..6% and 5.9%, respectively. CONCLUSION: Our study confirms that CCR is associated with improved survival over RT alone, with a tolerable increase in acute toxicity...
  20. ncbi State-of-the-art chemotherapy for advanced non-small cell lung cancer
    Sakkaraiappan Ramalingam
    Division of Hematology-Oncology, University of Pittsburgh School of Medicine, PA 15232, USA
    Semin Oncol 31:68-74. 2004
    ..Noncytotoxic, molecularly targeted agents currently under various phases of development for the treatment of lung cancer will serve as the cornerstones for further innovations in the treatment of NSCLC...
  21. ncbi Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm
    Arjun Pennathur
    Heart, Lung, and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA
    Ann Thorac Surg 85:1930-6; discussion 1936-7. 2008
    ..We report the long-term results of our phase II study of neoadjuvant chemotherapy, followed by esophagectomy and adjuvant chemotherapy for potentially resectable esophageal carcinoma...
  22. ncbi Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer
    C P Belani
    Department of Medicine, University of Pittsburgh Cancer Institute, PA 15213, USA
    J Clin Oncol 17:676-84. 1999
    ....
  23. ncbi Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer
    C P Belani
    University of Pittsburgh School of Medicine and the University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Semin Oncol 28:14-6. 2001
    ..All regimens were well tolerated. Arm 1 has the best therapeutic index and will exceed the median survival seen in previous phase III trials with traditional schedules of paclitaxel and carboplatin...
  24. ncbi Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial
    Chandra P Belani
    University of Pittsburgh School of Medicine, Lung and Thoracic Malignancies Program, University of Pittsburgh Cancer Institute, Cancer Pavilion, Floor 5, 5150 Centre Avenue Pittsburgh, PA 15232, USA
    Lung Cancer 53:231-9. 2006
    ..DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant...
  25. ncbi Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group
    Frank Fossella
    Division of Medical Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center Cancer Pavilion, 5150 Center Ave, Suite 570, Pittsburgh, PA 15232, USA
    J Clin Oncol 21:3016-24. 2003
    ..These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC...
  26. ncbi Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
    Suresh S Ramalingam
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 13:3605-10. 2007
    ..The primary objective of this study was to determine the recommended phase II doses of the novel histone deacetylase inhibitor vorinostat when administered in combination with carboplatin and paclitaxel...
  27. ncbi Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599
    Suresh S Ramalingam
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA
    J Clin Oncol 26:60-5. 2008
    ..We conducted a subset analysis of ECOG 4599 to determine the outcome for elderly patients...
  28. ncbi Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study
    Sakkaraiappan Ramalingam
    Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer Chemother Pharmacol 53:439-44. 2004
    ..CONCLUSIONS: The combination of carboplatin plus docetaxel is well tolerated and is effective for the treatment of patients with previously untreated advanced or metastatic non-small-cell lung cancer...
  29. ncbi Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study
    Suresh Ramalingam
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
    J Thorac Oncol 3:258-64. 2008
    ....
  30. ncbi Role of positron emission tomography in staging esophageal cancer
    J D Luketich
    Section of Thoracic Surgery, University of Pittsburgh Medical Center, Pennsylvania 15213, USA
    Ann Thorac Surg 64:765-9. 1997
    ..Conventional noninvasive staging of esophageal cancer is inaccurate. This study investigated the role of positron emission tomography (PET) in staging esophageal cancer...
  31. ncbi Emerging advances in the management of lung cancer
    Chandra P Belani
    Department of Medicine, University of Pittsburgh School of Medicine, PA 15232, USA
    Clin Lung Cancer 6:S60. 2004
  32. ncbi Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors
    Julie L Eiseman
    Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213 1863, USA
    Clin Cancer Res 13:2121-7. 2007
    ..Pretreatment plasma samples were also obtained from 12 healthy volunteers. Plasma IGFBP-2 and Her-2 ECD concentrations were quantitated by ELISA...
  33. ncbi Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers
    Ramesh K Ramanathan
    Molecular Therapeutics Drug Discovery Program, Biostatistics Department, Graduate School of Public Health, and Biostatistics Facility, University of Pittsburgh Cancer Institute, PA 15232, USA
    Clin Cancer Res 11:3385-91. 2005
    ..We did a phase I study of 17AAG to establish the dose-limiting toxicity and maximum tolerated dose and to characterize 17AAG pharmacokinetics and pharmacodynamics...
  34. ncbi Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Clin Cancer Res 13:1769-74. 2007
    ..The primary objective was to establish the dose-limiting toxicity (DLT) and recommended phase II dose of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) given twice a week...
  35. ncbi Radiosurgery for the treatment of spinal lung metastases
    Peter C Gerszten
    Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Cancer 107:2653-61. 2006
    ..The current study evaluated the efficacy of single-fraction radiosurgery for the treatment of spinal lung cancer metastases...
  36. ncbi Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors
    Ramesh K Ramanathan
    Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Clin Oncol 28:1520-6. 2010
    ..To define the maximum tolerated dose, toxicities, pharmacokinetics, and pharmacodynamics of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG)...
  37. ncbi Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells
    Taofeek K Owonikoko
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Int J Cancer 126:743-55. 2010
    ..This likely involves a vorinostat-mediated irreversible increase in DNA damage in the case of carboplatin and a reversible increase in microtubule stability in the case of paclitaxel...
  38. ncbi Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 57:465-74. 2006
    ..The pharmacokinetics of MGd were also evaluated...
  39. ncbi Recent advances in targeted therapy for non-small cell lung cancer
    Suresh Ramalingam
    University of Pittsburgh School of Medicine, Division of Hematology Oncology, Department of Medicine, Pittsburgh, PA, USA
    Expert Opin Ther Targets 11:245-57. 2007
    ..These developments have paved the way for a new era of tailor-made therapies based on clinical or molecular/genetic profiles in the treatment of NSCLC. This article reviews the recent advances in targeted therapy of advanced NSCLC...
  40. ncbi Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation
    Chandra P Belani
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    J Clin Oncol 21:2933-9. 2003
    ....
  41. ncbi Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors
    William C Zamboni
    Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Clin Cancer Res 10:5058-64. 2004
    ..In an effort to increase the dose administered per day and determine whether the daily dose or number of days of treatment influence toxicity, we performed a Phase I study of 9NC using intermittent schedules of administration...
  42. ncbi Results of clinical trials for locally advanced and metastatic nonsmall-cell lung cancer
    Sakkaraiappan Ramalingam
    Division of Hematology-Oncology, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, PA 15232, USA
    Semin Thorac Cardiovasc Surg 15:438-47. 2003
    ..Early results with some of the targeted agents studied for the treatment of NSCLC have generated a great deal of excitement. In this article, we review the results of recent clinical trials in locally advanced and metastatic NSCLC...
  43. ncbi Carboplatin/gemcitabine combination in advanced NSCLC
    Sakkaraiappan Ramalingam
    University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, USA
    Oncology (Williston Park) 18:21-6. 2004
    ..This regimen can also be used as a foundation for the development of innovative combinations with molecularly targeted agents...
  44. ncbi First-line chemotherapy for NSCLC: an overview of relevant trials
    Chandra P Belani
    Lung and Thoracic Cancer Program, University of Pittsburgh Cancer Institute and School of Medicine, UPMC Cancer Pavilion, 5150 Centre Avenue 5th Floor, Pittsburgh, PA 15232, USA
    Lung Cancer 38:13-9. 2002
    ..Hopes for further improvement in survival are focused on the combination of cytotoxic agents with novel molecularly-targeted drugs such as the anti-angiogenics and EGFR inhibitors...
  45. ncbi Emerging role of erlotinib (OSI-774) in non-small-cell lung cancer
    Chandra P Belani
    Department of Medicine, University of Pittsburgh School of Medicine, PA 15232, USA
    Clin Lung Cancer 6:S6. 2004
  46. ncbi Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patients
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Clin Oncol 20:4313-8. 2002
    ..To determine whether granulocyte-macrophage colony-stimulating factor (GM-CSF) would improve response to influenza vaccination in cancer patients...
  47. ncbi Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies
    Ramesh K Ramanathan
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer Chemother Pharmacol 55:354-60. 2005
    ..To improve the therapeutic index, we evaluated a weekly regimen of docetaxel in combination with capecitabine, and determined the maximum tolerated dose, toxicities and pharmacokinetics of this combination...
  48. ncbi Meaningful survival in lung cancer patients
    Sakkaraiappan Ramalingam
    Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Semin Oncol 29:125-31. 2002
    ..In this review, we discuss the impact of anemia and the treatment options that could contribute to a truly meaningful survival in lung cancer patients...
  49. ncbi Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma
    Chandra P Belani
    University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Semin Oncol 31:25-33. 2004
    ..Recent clinical data on new chemotherapeutic strategies for the treatment of lung, breast, and genitourinary cancers and myeloma will be presented in this review...
  50. ncbi Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer
    S Ramalingam
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Ann Oncol 15:247-51. 2004
    ..This combination was associated with a high incidence of myelosuppression and febrile neutropenia, at the doses evaluated...
  51. ncbi A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Cancer Chemother Pharmacol 64:777-83. 2009
    ..To evaluate the response to lapatinib, an inhibitor of epidermal growth factor receptors 1 and 2, in patients with advanced bilary tree cancer (BTC) and hepatocellular cancer (HCC)...
  52. ncbi Role of bevacizumab for the treatment of non-small-cell lung cancer
    Suresh Ramalingam
    Division of Hematolgoy Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Future Oncol 3:131-9. 2007
    ..This article discusses the recent data with bevacizumab in NSCLC and its potential application at various stages of NSCLC...
  53. ncbi Adjuvant and neoadjuvant therapy in non-small cell lung cancer
    Chandra P Belani
    Lung and Thoracic Cancer Program, University Cancer Institute, University of Pittsburgh School of Medicine, UPMC Cancer Pavilion, 5150 Center Avenue 5th Floor, Pittsburgh, PA 15232, USA
    Semin Oncol 32:S9-15. 2005
    ..Neoadjuvant chemotherapy may also downstage the disease before surgery and decrease perioperative tumor seeding, and molecularly targeted approaches with neoadjuvant therapy appear promising...
  54. ncbi A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 13:2109-14. 2007
    ..Objectives of this study were to determine safety, tolerability, pharmacodynamics, and pharmacokinetics of PX-12, a small-molecule inhibitor of Trx-1...
  55. ncbi Molecularly-targeted therapies for non-small cell lung cancer
    Suresh Ramalingam
    Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Expert Opin Pharmacother 6:2667-79. 2005
    ..The exciting results of this study represent an important advance in the treatment of patients with advanced NSCLC...
  56. ncbi Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors
    Laura L Jung
    Molecular Therapeutics and Drug Discovery Program, University of Pittsburgh Cancer Institute, PA 15213, Pittsburgh, USA
    Cancer Chemother Pharmacol 54:487-96. 2004
    ..97, respectively. The recovery of 9NC and 9AC in the urine was <15%. CONCLUSIONS: There was significant interpatient and intrapatient variability in the disposition of 9NC and 9AC. 9NC and 9AC undergo primarily nonrenal elimination...
  57. ncbi Basic treatment considerations: chemotherapy
    Sakkaraiappan Ramalingam
    Division of Hematology-Oncology, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, 5150 Center Avenue, UPMC Cancer Pavilion, Pittsburgh, PA 15232, USA
    Hematol Oncol Clin North Am 18:13-28. 2004
    ..In the upcoming years, we will learn effective means to incorporate molecularly targeted therapies to existing treatment paradigms in lung cancer...
  58. ncbi Cyclooxygenase-2 inhibitors in lung cancer
    Sakkaraiappan Ramalingam
    Division of Hematology/Oncology, Lung and Thoracic Cancer Program, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, PA 15323, USA
    Clin Lung Cancer 5:245-53. 2004
    ..These effects have been documented in several preclinical studies. Clinical efficacy of COX-2 inhibitors in the treatment of NSCLC is presently undergoing evaluation...
  59. ncbi Women and lung cancer: epidemiology, tumor biology, and emerging trends in clinical research
    Chandra P Belani
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States
    Lung Cancer 55:15-23. 2007
    ..To further improve survival in this disease, both clinical characteristics and tumor biology should be considered in the development of new treatment options...
  60. ncbi Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer
    Roy S Herbst
    The M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:4743-50. 2007
    ..A single-arm phase I and II study of bevacizumab plus erlotinib demonstrated encouraging efficacy, with a favorable safety profile...
  61. ncbi Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database
    Taofeek K Owonikoko
    Emory Winship Cancer Institute, 1365 Clifton Rd, Ste C 5090, Atlanta, GA 30322, USA
    J Clin Oncol 25:5570-7. 2007
    ..To study the burden and outcome of lung cancer in the elderly, particularly for patients aged 80 years and older...
  62. ncbi Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer
    Chandra P Belani
    Penn State Cancer Institute, H072, 500 University Drive, PO Box 850, Hershey, PA 77030, USA
    J Clin Oncol 26:468-73. 2008
    ....
  63. ncbi Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599, USA
    J Clin Oncol 26:650-6. 2008
    ....
  64. ncbi Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    Joan H Schiller
    University of Wisconsin Hospital and Clinics, Madison, USA
    N Engl J Med 346:92-8. 2002
    ..CONCLUSIONS: None of four chemotherapy regimens offered a significant advantage over the others in the treatment of advanced non-small-cell lung cancer...
  65. ncbi Ongoing and future trials of biologic therapies in lung cancer
    Paul A Bunn
    University of Colorado Cancer Center, Denver, CO, USA
    Lung Cancer 41:S175-86. 2003
    ..Many new agents have been developed to attack these targets. This article describes current and proposed trials for these new targeted therapies in both small cell and non-small cell lung cancers...
  66. ncbi Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer
    Suresh Ramalingam
    Emory Winship Cancer Institute, Atlanta, Georgia, USA
    Cancer 113:542-6. 2008
    ....
  67. ncbi Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer
    Chandra P Belani
    Lung and Thoracic Cancer Program, University of Pittsburgh Cancer Institute, PA
    Semin Oncol 29:4-9. 2002
    ....
  68. ncbi Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer
    John V Heymach
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 25:4270-7. 2007
    ..The activity of vandetanib plus docetaxel was assessed in patients with previously treated non-small-cell lung cancer (NSCLC)...
  69. ncbi Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial
    Mark G Kris
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and the Weill Medical College of Cornell University, New York, NY 10021, USA
    JAMA 290:2149-58. 2003
    ..04) and diarrhea (P =.006). CONCLUSIONS: Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy...
  70. ncbi Bevacizumab extends survival for patients with nonsquamous non-small-cell lung cancer
    Chandra P Belani
    Clin Lung Cancer 6:267-8. 2005
  71. ncbi Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial
    David Cella
    Evanston Northwestern Healthcare and Northwestern University, 1001 University Place, Ste 100, Evanston, IL 60201, USA
    J Clin Oncol 23:2946-54. 2005
    ..Among these NSCLC patients treated with gefitinib, symptom improvement was complementary to and, for most patients, preceded evidence of radiographic regression...
  72. ncbi The ANITA trial seals the deal for adjuvant therapy in non-small-cell lung cancer
    Chandra P Belani
    Clin Lung Cancer 6:331-2. 2005
  73. ncbi Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib
    Chandra P Belani
    Clin Lung Cancer 6:203-4. 2005
  74. ncbi Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program
    Pasi A Janne
    Lowe Center for Thoracic Oncolgy, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Lung Cancer 7:40-6. 2005
    ..Before the regulatory approval of pemetrexed, an expanded access program (EAP) provided access to eligible patients with malignant pleural or peritoneal mesothelioma...
  75. ncbi Combining targeted agents in lung cancer
    Chandra P Belani
    Clin Lung Cancer 6:138. 2004
  76. ncbi Optimizing first-line treatment options for patients with advanced NSCLC
    Heather Wakelee
    Stanford University, Stanford, California, USA
    Oncologist 10:1-10. 2005
    ..Each incremental advance demonstrates that progress can be made in first-line treatment of advanced NSCLC...
  77. ncbi PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2
    Kathy S Albain
    Loyola University, Chicago Medical Center, Maywood, IL 60153, USA
    Clin Lung Cancer 7:417-9. 2006
  78. ncbi Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program
    Coleman K Obasaju
    Eli Lilly and Company, Lilly Corporate Center, Drop Code 6831, Indianapolis, IN 46285, USA
    Lung Cancer 55:187-94. 2007
    ..An expanded access program (EAP) provided patient access to pemetrexed prior to its commercial availability. The current report consists of US patients in the EAP who had chemotherapy naïve pleural mesothelioma...
  79. ncbi Lung cancer: looking ahead in 2004
    Chandra P Belani
    Clin Lung Cancer 5:200. 2004
  80. ncbi Elderly patients with advanced non-small-cell lung cancer
    Chandra P Belani
    Clin Lung Cancer 5:76. 2003
  81. ncbi Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program
    Pasi A Janne
    Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Thorac Oncol 1:506-12. 2006
    ..To gather additional efficacy and safety data of pemetrexed/cisplatin and pemetrexed alone in previously treated patients, we examined patients treated on the Eli Lilly and Company expanded access program (EAP)...
  82. ncbi Docetaxel in advanced non-small cell lung cancer
    Heather Wakelee
    Stanford University School of Medicine, Stanford University Cancer Center, 875 Blake Wilbur Dr, Stanford, CA 94305 5826, USA
    Expert Rev Anticancer Ther 5:13-24. 2005
    ..This article reviews recent studies of docetaxel as a single agent and in combination regimens with cytotoxic and more recent targeted agents in the management of advanced NSCLC...